Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab
Article
Bumes, Elisabeth, Rzonsa, Sarah, Hutterer, Markus, Proescholdt, Martin, Bogdahn, Ulrich, Riemenschneider, Markus J., Uhl, Martin, Wendl, Christina and Hau, Peter (2016) Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab. Journal of Neuro-Oncology 127 (1), pp. 191-200.Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Journal of Neuro-Oncology | ||||
| Publisher | Springer | ||||
| Place of Publication | NEW YORK | ||||
| Volume | 127 | ||||
| Number of Issue or Book Chapter | 1 | ||||
| Page Range | pp. 191-200 | ||||
| Date | 2016 | ||||
| Date of publication | 17 Mar 2020 11:01 | ||||
| Institutions | Medicine > Lehrstuhl für Neurochirurgie Medicine > Lehrstuhl für Neurologie | ||||
| Identification Number |
| ||||
| Keywords | SINGLE-AGENT BEVACIZUMAB; PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT MALIGNANT GLIOMA; RADIATION-THERAPY; METRONOMIC CHEMOTHERAPY; DAILY TEMOZOLOMIDE; PLUS IRINOTECAN; PROGRESSION; MULTIFORME; Glioblastoma; High-grade glioma; Bevacizumab; Temozolomide; Hypertension; CTCAE | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 41860 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric